Abstract
The EMA has approved cladribine tablets for the treatment of multiple sclerosis. The drug is not new, and the journey to its approval has been a long one, but the old concepts that cladribine therapy are based on provide a new option for the possibility of drug-free remission.
References
Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).
Montalban, X. et al. Efficacy of cladribine tablets as add-on to IFN-beta therapy in patients with active relapsing MS: final results from the phase II ONWARD Study [abstract]. Neurology 86 (Suppl. 6), P3.029 (2016).
Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 13, 257–267 (2014).
Pakpoor, J. et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol. Neuroimmunol. Neuroinflamm. 2, e158 (2015).
Giovannoni, G. et al. Clinical efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis (RRMS): final results from the 120-week phase IIIb extension trial to the CLARITY Study [abstract]. Neurology 86 (Suppl. 16), P3.028 (2016).
Acknowledgements
H.W. is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS). The author is grateful to Heike Blum for assistance in drawing of Figure 1 and to Nick Fulcher for language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author receives honoraria for acting as a member of Scientific Advisory Boards and as a consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, as well as speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Global. He is acting as a paid consultant for Abbvie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme and the Swiss Multiple Sclerosis Society. His research is partially funded by Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG and Sanofi-Genzyme.
Supplementary information
Supplementary information S1 (box)
Features, facts and questions about immune reconstitution therapies/induction principles (DOC 29 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Wiendl, H. Cladribine — an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol 13, 573–574 (2017). https://doi.org/10.1038/nrneurol.2017.119
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.119
- Springer Nature Limited
This article is cited by
-
Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy
Journal of Neuroinflammation (2023)
-
Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
Scientific Reports (2023)
-
Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis
Journal of Neuroinflammation (2022)
-
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology
CNS Drugs (2021)
-
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
Neurotherapeutics (2021)